Timothy R.H. Regnault

1 month ago | biorxiv.org | Baylea N Davenport |Alyssa Williams |Timothy R.H. Regnault |Helen Jones

AbstractFetal development in an adverse in utero environment significantly increases the risk of hypertension and cardiovascular disease. The kidneys play a pivotal role in the regulation of blood pressure and cardiovascular function, and perturbations in kidney structure and molecular profile are often demonstrated in offspring born fetal growth restricted (FGR).

Nov 3, 2024 | biorxiv.org | Baylea N Davenport |Alyssa Williams |Timothy R.H. Regnault |Helen Jones

AbstractFetal development in an adverse in utero environment significantly increases the risk of developing metabolic diseases in later life, including dyslipidemia, non-alcoholic fatty liver diseases and diabetes. The aim of this study was to determine whether improving the in utero fetal growth environment with a placental nanoparticle gene therapy would ameliorate fetal growth restriction (FGR)-associated dysregulation of fetal hepatic lipid and glucose metabolism-related signaling pathways.